Table 1: Pharmacological profile of the new synthetic cannabinoids

| | 1-pentyl | 1-(5-fluoropentyl) | 1-butyl | 1-(4-pentenyl) | 1-(5-hexynyl) | 1-(cyclohexylmethyl) | 1-(cyclopropylmethyl) | 1-(2-morpholinoethyl) | 1-(2-dimethylaminoethyl) | 1-(2-piperidinylethyl) | 1-(2-pyrrolidinylethyl) | 1-(2-methylpentyl) | 1-(3-methylbutyl) | 1-(3-methylpentyl) | 1-(4-methylpentyl) | 1-(5-methylhexyl) | 1-(6-methylheptyl) | 1-(7-methyloctyl) | 1-(8-methylnonyl) | 1-(9-methyldecyl) | 1-(10-methylundecyl) | 1-(11-methyldodecyl) | 1-(12-methyltridecyl) | 1-(13-methyltetradecyl) | 1-(14-methylpentadecyl) | 1-(15-methylhexadecyl) | 1-(16-methylheptadecyl) | 1-(17-methyloctadecyl) | 1-(18-methylnonadecyl) | 1-(19-methyleicosyl) | 1-(20-methylheneicosyl) | 1-(21-methyldocosyl) | 1-(22-methyltricosyl) | 1-(23-methyltetracosyl) | 1-(24-methylpentacosyl) | 1-(25-methylhexacosyl) | 1-(26-methylheptacosyl) | 1-(27-methyloctacosyl) | 1-(28-methylnonacosyl) | 1-(29-methyltriacontyl) | 1-(30-methylhentriacontyl) | 1-(31-methyldotriacontyl) | 1-(32-methyltritriacontyl) | 1-(33-methyltetratriacontyl) | 1-(34-methylpentatriacontyl) | 1-(35-methylhexatriacontyl) | 1-(36-methylheptatriacontyl) | 1-(37-methyloctatriacontyl) | 1-(38-methylnonatriacontyl) | 1-(39-methylhentetracontyl) | 1-(40-methyltetracontyl) | 1-(41-methyltetracontyl) | 1-(42-methyltetracontyl) | 1-(43-methyltetracontyl) | 1-(44-methyltetracontyl) | 1-(45-methyltetracontyl) | 1-(46-methyltetracontyl) | 1-(47-methyltetracontyl) | 1-(48-methyltetracontyl) | 1-(49-methyltetracontyl) | 1-(50-methyltetracontyl) | 1-(51-methyltetracontyl) | 1-(52-methyltetracontyl) | 1-(53-methyltetracontyl) | 1-(54-methyltetracontyl) | 1-(55-methyltetracontyl) | 1-(56-methyltetracontyl) | 1-(57-methyltetracontyl) | 1-(58-methyltetracontyl) | 1-(59-methyltetracontyl) |